Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Gemtuzumab ozogamicin (GO), a calicheamicin-conjugated mAb against CD33, has been used in the treatment of acute myeloid leukemia (AML). We evaluated the impact of the addition of GO to standard chemotherapy and hematopoietic stem cell transplant (HCT) in patients withFLT3/ITD. We analyzed children...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-04, Vol.22 (8), p.1951-1957
Hauptverfasser:	Tarlock, Katherine, Alonzo, Todd A, Gerbing, Robert B, Raimondi, Susana C, Hirsch, Betsy A, Sung, Lillian, Pollard, Jessica A, Aplenc, Richard, Loken, Michael R, Gamis, Alan S, Meshinchi, Soheil
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aminoglycosides - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Child Child, Preschool Female fms-Like Tyrosine Kinase 3 - genetics Follow-Up Studies Gene Duplication Hematopoietic Stem Cell Transplantation Humans Infant Infant, Newborn Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Male Prognosis Recurrence Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!